Drillon A, et al. Registrational results of LIBRETTO-001: a phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancer. Abstract PL02.08. WCLC 2019, 7-10 september, Barcelona, Spanje.
Doorbraak in behandeling van maag- en slokdarmkanker
jan 2024 | Immuuntherapie, Maag-darm-leveroncologie